Navigation Links
Jazz Pharmaceuticals Announces Second Quarter 2014 Financial Results And Updated Guidance
Date:8/5/2014

al future results, particularly in light of the effect of various acquisition and divestiture transactions effected by the company.  They are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP.  Jazz Pharmaceuticals' management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate its business and make operating decisions. Compensation of executives is based in part on the performance of the company's business based on certain of these non-GAAP financial measures. In addition, Jazz Pharmaceuticals believes that the presentation of these non-GAAP financial measures is useful to investors because it enhances the ability of investors to compare its results from period to period and allows for greater transparency with respect to key financial metrics the company uses in making operating decisions, and also because the company's investors and analysts regularly use them to model and track the company's financial performance.

Investors should note that these non-GAAP financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Because of the non-standardized definitions, the non-GAAP financial measures as used by Jazz
'/>"/>

SOURCE Jazz Pharmaceuticals plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Cumberland Pharmaceuticals Reports Second Quarter 2014 Financial Results
2. Avanir Pharmaceuticals to Participate in Two Conferences in August
3. Heritage Pharmaceuticals Inc. Signs Exclusive Development Supply & Distribution Agreement with Dexcel Ltd.
4. Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
5. Jazz Pharmaceuticals Announces Participation at Canaccord Genuity Conference on August 13
6. Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Updates LGND Research Report with New Material Information
7. Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
8. Pharmaceuticals Learning the Language of the New Healthcare Landscape
9. Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
10. Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
11. Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... ST. LOUIS , Oct. 1, 2014  Express ... its two nationally available 2015 Express Scripts Medicare ® ... retail pharmacy network featuring Walgreens (NYSE: WAG ... obtain more value, choice and clinical support  for their ... the Express Scripts Medicare Value or ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal Philips ... today announced its eCareCoordinator and eCareCompanion telehealth applications ... and Drug Administration (FDA). A part of Philips ... , eCareCoordinator and eCareCompanion are focused on patient ... clinical applications to be available through the cloud-based ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... MASI ) announced today that it will release first ... the market closes on May 2, 2012. The conference call to ... ET) and will be hosted by Joe Kiani, Chairman and Chief ... Chief Financial Officer. A live webcast of the conference ...
... 2012 Financial executives in the medical device manufacturing ... burden of its related compliance costs will have a ... a survey conducted by KPMG LLP, the audit, tax ... companies are already contemplating actions such as price increases ...
Cached Medicine Technology:Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2 2Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2 3KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post ... for vulnerable family members. , Life insurance plans provide ... the family should always carry a life insurance policy ... rest of the family. , Clients can choose ... from temporary coverage or from a permanent policy. No ...
(Date:10/1/2014)... October 01, 2014 First Warning Systems, ... circadian cellular changes throughout the body, announced the company ... better address the company’s breadth of upcoming product releases. ... cancer screening technology. , “Our initial focus will be ... which detects abnormal circadian cellular changes over time,” said ...
(Date:10/1/2014)... 2014 Farmington Company today announced ... mission and visual identity helping brokers, consultants and ... them to create greater benefit communication synergies. They ... on empowering customers to better leverage Farmington Company’s ... jewel of the rebrand is the refreshed tagline: ...
(Date:10/1/2014)... Hills, California (PRWEB) October 01, 2014 ... expert, Dr. Kathleen Mojas is celebrating 20 years of ... has assisted hundreds of people to achieve greater joy ... an important list of warning signs and suggestions for ... , Dr. Mojas explains: “Believe it or not, ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... Canadian study finds increase in non-serious side effects , , ... compounds called cannabinoids from the marijuana plant don,t increase ... with an increase in some non-serious side effects, Canadian ... Montreal and the University of British Columbia (UBC) examined ...
... introduces its Contract Research Development as an invaluable resource to medical ... ... 2008 -- Zeus, Inc. introduced its Contract Research Development at the ... the Jacob K. Javits Convention Center in New York. Showcasing ...
... its wholly-owned subsidiary Embryome Sciences, Inc. announced ... International Embryome Initiative, an international collaboration with ... first systematic map of all the cell ... In a paper published today titled “The ...
... /PRNewswire-FirstCall/,-- Schering-Plough Corp. (NYSE: SGP ) and ... the withdrawal of the New Drug Application (NDA) ... terminated the Schering-Plough/Merck Pharmaceuticals,respiratory joint venture, which was ... fixed-combination product that would combine loratadine and,montelukast. This ...
... augment MDS Analytical Technologies, cellular ... ... /PRNewswire-FirstCall/ - MDS Analytical,Technologies, a leader in innovative solutions ... has acquired California-based,Blueshift Biotechnologies (Sunnyvale, CA) for $13 million. ...
... Clinical Development Program Investigating Golimumab in the ... Basis for the Application, HORSHAM, Pa., June ... License Application (BLA) has been submitted to the ... of golimumab,(CNTO 148) as a monthly subcutaneous treatment ...
Cached Medicine News:Health News:Drugs With Marijuana Compounds Don't Boost Adverse Events 2Health News:Contract Research Development Debuts at MD&M Touting Expertise, Innovation and Collaboration 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 3Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 4Health News:MDS Analytical Technologies Acquires Blueshift Biotechnologies 2Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: